ArticleAbdominal radiology (New York)2026
A clinical and contrast-enhanced CT-based model for preoperative prediction of CK19- and GPC3-positive dual-phenotype hepatocellular carcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo explore the predictive value of preoperative clinical and multiphase dynamic contrast-enhanced CT (CECT)-based qualitative and quantitative features for identifying Cytokeratin 19 (CK19)- and Glypican 3 (GPC3)-positive dual-phenotype hepatocellular carcinoma (DPHCC_CG+). MATERIALS AND
methodsA total of 363 HCC patients who received preoperative CECT and surgical resection from two medical centers were retrospectively included. Patients were divided into DPHCC_CG+ (CK19- and GPC3-positive) or Non-DPHCC_CG+ (CK19- and/or GPC3-negative) groups based on histopathology. Qualitative and quantitative CECT features, along with clinical variables, were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of DPHCC_CG+. Three predictive models (CT qualitative-clinical, CT quantitative-clinical and combined model) were developed in the training cohort and externally validated. Model performance was assessed and compared using receiver operating characteristic (ROC) analysis and the DeLong test.
resultsBoth the CT qualitative-clinical and CT quantitative-clinical models demonstrated good predictive performance for identifying DPHCC_CG + in both the training and external validation cohorts (AUCs > 0.79). Independent predictors of DPHCC_CG+ included serum AFP ≥ 400 ng/mL, presence of mosaic appearance, arterial phase tumor-to-aorta attenuation ratio (A-TAR ≤ 0.262), and delayed phase normalized washout ratio (D-NWR ≤ -0.141). The combined model integrating these predictors achieved optimal diagnostic performance, with AUCs of 0.878 (95% CI: 0.822-0.935) in the training cohort and 0.806 (95% CI: 0.723-0.889) in the external validation cohort.
conclusionThe combined model integrating preoperative serum AFP level with CECT qualitative and quantitative parameters enables effective, noninvasive identification of DPHCC_CG+ before treatment, providing potential clinical value for risk stratification and personalized management of HCC patients.
Indexed as
Identifiers
42171741What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.